Advertisement

Special Characteristics of Pharmaceuticals Related to Environmental Fate

  • V. L. Cunningham

Keywords

Distribution Coefficient Fecal Coliform Active Pharmaceutical Ingredient Salt Form Environmental Risk Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ballie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196CrossRefGoogle Scholar
  2. Barton DA, McKeown JJ (1991) Field verification of predictive modeling of organic compound removal by biological wastewater treatment processes. Environ Prog 10:96–103CrossRefGoogle Scholar
  3. Bryn SR (1982) Solid state chemistry of drugs. Academic Press, New YorkGoogle Scholar
  4. FDA Food and Drug Administration (1987) Environmental Assessment Technical Assistance Document, Section 3.08Google Scholar
  5. Haleblian J (1975) Characterisation of habits and crystalline modification of solids and their pharmaceutical applications J Pharm Sci 64:1269–1288CrossRefGoogle Scholar
  6. Hansch C, Leo A (1995) Exploring QSAR: fundamentals and applications in chemistry and biology. American Chemical Society, Washington, DC (Chapter 4)Google Scholar
  7. Henwood SQ, LiebenbergW, Tiedt LR, Lotter AP, de Villiers MM (2001) Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates. Drug Dev Ind Pharm 27:1017–1030Google Scholar
  8. Karcher W, Deviller J (eds) (1990) Practical applications of quantitative structure-activity relationships (QSAR) in environmental chemistry and toxicology. Kluwer Academic Publishers, The Netherlands, pp 25–59Google Scholar
  9. Kozak RG, D’Haese I, Verstraete W (2001) Pharmaceuticals in the environment: focus on 17 α-ethinyloestradiol. In: Kümmerer K (ed) Pharmaceuticals in the environment, 1st edn. Springer-Verlag, Berlin, p 50Google Scholar
  10. La Du BN, Mandel HG, Way EL (eds) (1979) Fundamentals of drug metabolism and drug disposition. Robert E. Krieger Publishing Company, Huntington, New YorkGoogle Scholar
  11. Lyman WJ, Reehl WF, Rosenblatt DH (eds) (1990) Handbook of chemical property estimation methods. American Chemical Society, Washington, DC (Chapters 1, 2, 4, 5)Google Scholar
  12. Möhle E, Metzger JW (2001) Drugs in municipal sewage effluents: screening and biodegradation studies, pharmaceuticals and personal care products in the environment. In: Daughton CG, Jone-Lepp T (eds) Scientific and regulatory issues. ACS Symposium Series 791:203Google Scholar
  13. Ternes T, Krechel P, Mueller J (1999) Behavior and occurrence of estrogens in municipal sewage treatment plants – II. Aerobic batch experiments with activated sludge. Sci Total Environ 225:91–99CrossRefGoogle Scholar
  14. Tolls J (2001) Sorption of veterinary pharmaceuticals in soils: a review. Environ Sci Techn 35:3397–3406CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • V. L. Cunningham
    • 1
  1. 1.ClaxoSmithKlinePhiladelphiaUSA

Personalised recommendations